文献速递前列腺癌

临床高风险前列腺癌患者接受机器人辅助根治性前列腺切除术的功能结局:多机构分析

Functional outcomes of clinically high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a multi-institutional analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-05-02

该多机构回顾性分析纳入769例D'Amico高风险前列腺癌患者,评估机器人辅助根治性前列腺切除术后3年尿控与性功能恢复情况。术后36个月尿控恢复率为91.2%,术前勃起功能正常者中69.0%恢复性功能。年龄和手术年份与尿控及性功能恢复相关,术前SHIM评分、神经保留程度、pT3b-T4期及手术切缘与性功能恢复相关。

要点

  • 术后36个月尿控恢复率为91.2%,性功能恢复率为69.0%(术前SHIM≥17者)。
  • 年龄和手术年份与尿控及性功能恢复相关。
  • 术前SHIM评分、神经保留程度、pT3b-T4期及手术切缘与性功能恢复相关。

核心结论

  • 接受机器人辅助根治性前列腺切除术的D'Amico高风险前列腺癌患者术后12个月后仍可能继续恢复尿控和性功能,3年随访结局良好。
  • 适当的患者选择和咨询可能有助于设定术后功能恢复的合理预期。

研究设计与样本

  • 回顾性分析前瞻性维护数据库,纳入2001年至2014年在美国和欧洲两家三级医疗中心接受机器人辅助根治性前列腺切除术的769例D'Amico高风险前列腺癌患者。

主要发现

  • 队列平均年龄62.3岁,62.1%患者为≥pT3a期。
  • 87.7%患者接受了单侧或双侧神经保留机器人辅助根治性前列腺切除术。
  • 术后12、24和36个月尿控恢复的Kaplan-Meier估计值分别为85.2%、89.1%和91.2%。
  • 术前勃起功能正常(术前SHIM≥17;n=548;71.3%)的男性中,术后12、24和36个月性功能恢复率分别为33.8%、52.3%和69.0%。
  • 患者年龄和手术年份与尿控及性功能恢复相关;术前SHIM评分、神经保留程度、pT3b-T4期疾病和手术切缘与观察期间性功能恢复相关。

关键数值与推荐

  • 尿控恢复定义为每天0个尿垫或1个安全衬垫。
  • 性功能恢复定义为男性性健康量表(SHIM)评分≥17。
  • 敏感性分析分别以每天0个尿垫和勃起足以性交作为尿控和性功能恢复的终点,结果相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To ascertain 3-year urinary continence (UC) and sexual function (SF) recovery following robot-assisted radical prostatectomy (RARP) for clinically high-risk prostate cancer (PCa). METHODS: Retrospective analyses of a prospectively maintained database for 769 patients with D'Amico high-risk PCa undergoing RARP at two tertiary care centers in the United States and Europe between 2001 and 2014. The association between time since RARP and recovery of UC (defined as 0 pad/one safety liner per day) and SF (defined as sexual health inventory for men (SHIM) score ⩾17) was tested in separate preoperative and post-operative Cox-proportional hazards regression models. Sensitivity analyses were conducted using continence 0 pad per day and erection sufficient for intercourse as end points for UC and SF recovery, respectively. RESULTS: Mean age of the cohort was 62.3 years, and 62.1% harbored ⩾PT3a disease. Nerve sparing (unilateral or bilateral) RARP was performed in 87.7% of patients. Kaplan-Meier estimates of UC recovery at 12, 24 and 36 months after surgery was 85.2%, 89.1% and 91.2%, respectively, while 33.8, 52.3 and 69.0% of preoperatively potent men (preoperative SHIM ⩾17; n=548; 71.3%) recovered SF. Similar results were noted in sensitivity analyses. Patient age and year of surgery were associated with UC and SF recovery; additionally, preoperative SHIM score, degree of nerve sparing, pT3b-T4 disease and surgical margins were associated with SF recovery over the period of observation. CONCLUSIONS: Patients with D'Amico high-risk PCa treated with RARP may continue to recover UC and SF beyond 12 months of surgery and show promising outcomes at 3-year follow-up. Appropriate patient selection and counseling may aid in setting realistic expectations for functional recovery post RARP.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Abdollah F, Dalela D, Sood A, et al. Functional outcomes of clinically high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a multi-institutional analysis. Prostate Cancer Prostatic Dis. 2017. PMID: 28462944. doi:10.1038/pcan.2017.26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。